Industry Insights Seminar Series
The Industry Insights Seminar Series is hosted by the Business Partnerships Office
- 12.00 -1.00 pm
- In person and online
- In person at Institute of Developmental & Regenerative Medicine (IDRM), Old Road Campus, Headington, OX3 7TY
- Networking & 1:1 meeting opportunities
The Industry Insight Seminars provide the opportunity for Oxford scientists to attend a scientific seminar of interest and to network with industry scientists. Selected industry speakers provide seminars that are scientific in nature, across a range of medical or health topics. Speakers are encouraged to bring along colleagues to facilitate networking; one to one meetings can be facilitated upon request. Seminars are suitable for all scientists with some knowledge or interest in each topic area, from PhD students to PIs. Although mostly aimed at an academic audience, those located in the BioEscalator and Wood Centre, as well as local spinouts, are welcome to attend.
Please contact Sheena Lee if you have any questions or have an industry partner you would like to invite to speak
16th January 2025: Progress Towards Targeted Immunotherapy for Cancer
Presenter: Dr Robert Wilkinson - VP Oncology Research
Company: Immunocore
Description: Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy.
Their mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines.
Built on proprietary ImmTAX platform, they have a diverse pipeline of bispecific therapies across a broad range of indications, including multiple cancers, HIV and HBV
Past events
2024
Kuldeep Singh, Mradul Kanugo - Softude, Dr. Joseph Davids - Imperial College London- From Paperwork to Patients: AI in Helathcare
Dr Thomas Freeman - Johnson & Johnson Innovative Medicine - The impacts of omics data on translational science
Professor Nadeem Sarwar - Novo Nordisk - Prevention is better than cure – realising a sustainable new paradigm to predict and pre-empt obesity and its consequences
Nicholas Zoulias - Azenta - Harnessing the power of multiomics from a single sample to explore tumor heterogeneity and advancing immuno-oncology
Dr Shea Hamilton - Somalogic - The transformative role of Somascan for protein biomarker discovery, validation and translation
Dr Sarantis Chlamydas – Olink - Precision proteomics broadens MultiOmics repertoire and enables biomarker discovery
Christel Iffland, Chris Birchall - OmniAb-Opening the Barn Door to Antibody Discovery with OmniAb
Jayne Wallace - Oxford Nanopore - Democratising sequencing: Latest from Oxford Nanopore Technologies
Luke Devey – Quell - Restoring the balance with Regulatory T Cell Therapies/ Opportunities and Challenges in Biotech, 2024
2023
Balaji Modhagala, Subhagata Chattopadhyay – SquareML - AI-ML in Healthcare: Predicting 30-day Post-discharge Unplanned Readmission Risks in the Elderly - a Use Case
Casper Wilstrup – Abzu - Augmenting Drug Discovery with AI
Quin Wills - Ochre Bio - Maintaining Human Livers Outside of the Body
Jo Howson - Novo Nordisk - Genetics and Drug Discovery
onathan Kwok – Infinitopes - UK positioning as a cancer vaccine superpower- hyperbole or reality? Infinitopes as a CRUK-led cancer vaccine spinout from the Oxford ecosystem
Lisa Caproni - Touchlight - The Making of DNA: The role of enzymatic doggybone DNA in enabling future genetic medicines
Daniel Tomé, Mariana Fontes – Olink - Understanding human disease in the post-genomics era
Hussein - Al-Mossawi – AstraZeneca - Targeting type 1 IFN in immune-mediated inflammatory disease
2022
Iris-Valerie Stracke – Psious - Virtual reality and mental health
William Drewe, Martin Main - Medicines Discovery Catapult - Advancing UK Medicines Discovery through Innovative Partnerships
Jack Pearson - Natural Cycles - Natural Cycles: Revolutionising research in Women's Health
Jason Crain – IBM - Physical modelling and machine intelligence for accelerated discovery
Yatish Lad - Oxford BioMedica - Gene therapy – coming of age
Martin-Immanuel Bittner – Arctoris - Combining robotics and AI: the emergence of data-driven drug discovery
Anna Hakes – BridgeBio - Bridgebio Pharma: turning translational academic research into medicines for patients with genetic diseases
2021
Ramneek Gupta - Novo Nordisk Research Centre Oxford - Target Discovery Opportunities using Machine Learning on Longitudinal Patient Journeys
Anjan Thakurta – BMS- Translational Fellowships: Perspectives from a BMS mentor and 5 Oxford fellows
David Price -Vertex - Humanising drugs
Katharina Duerr - OMass - Development of Novel Medicines using high resolution native mass spectrometry of intact protein assemblies
Dr Manuela Zonca – PsiOxus - Tumour re-engineering
Joanna Gould – VisusNano - Novel drug-delivery in ophthalmology
Jane Osbourn, Paul Kellam – BIA - Accelerating Covid-19 Antibody Discovery Through Industry-Academia Consortium
Joe Fitchett - Mologic - Transforming the path for equitable access to rapid diagnostics for epidemics
Ilona Gutcher – Bayer - Targeting the Aryl Hydrocarbon Receptor (AHR) as a novel immunotherapy for the treatment of cancer
David Lowe – Evox - Exosome-Based Therapies for the Treatment of Rare Genetic Diseases